Cytokinetics EVP sells 14,000 shares after option exercise
CYTOKINETICS INC EVP and Chief Commercial Officer Andrew Callos exercised 14,000 non-qualified stock options for Common Stock at $23.26 per share and, on the same date, sold 14,000 shares at $79.88 per share under a Rule 10b5-1 trading plan.
Rhea-AI Filing Summary
CYTOKINETICS INC EVP and Chief Commercial Officer Andrew Callos exercised 14,000 non-qualified stock options for Common Stock at $23.26 per share and, on the same date, sold 14,000 shares at $79.88 per share under a Rule 10b5-1 trading plan. Following the exercise, he reports 10,000 stock options remaining. The option grant vests over four years, with 25% after one year and the balance vesting monthly over 36 months, subject to continued employment.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 14,000 shares ($793K approx. pre-tax spread)
Exercise and Sale
3 txns
Insider
Callos Andrew
Role
EVP, Chief Commercial Officer
Sold
14,000 shs ($1.12M)
Approx. gross sale proceeds
$1.12M
Approx. exercise cost
$326K
Approx. pre-tax spread
$793K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Non-Qualified Stock Option (Right to Buy) F1 | 14,000 | $0.00 | $0.00 |
| Exercise | Common Stock | 14,000 | $23.26 | $326K |
| Sale | Common Stock | 14,000 | $79.88 | $1.12M |
Holdings After Transaction:
Non-Qualified Stock Option (Right to Buy) — 10,000 contracts (Direct);
Common Stock — 58,555 shares (Direct)
Footnotes (1)
- F1. Stock options will vest over 4 years from the date of the grant, with 1/4th of the shares underlying the reporting person's option vesting on the one-year anniversary of the grant date and the remaining shares thereafter vesting monthly at a rate of 1/48th of the shares underlying the reporting person's option over the subsequent 36 months, subject to the reporting person's continued employment with the Issuer.
Key Figures
Options Exercised: 14,000 shares
Option Exercise Price: $23.26 per share
Shares Sold: 14,000 shares
+4 more
7 metrics
Options Exercised
14,000 shares
Non-Qualified Stock Options exercised on 2026-07-30
Option Exercise Price
$23.26 per share
Exercise price for 14,000 Non-Qualified Stock Options
Shares Sold
14,000 shares
Common Stock sold on 2026-07-30
Sale Price
$79.88 per share
Price for 14,000 Common Stock shares sold
Options Remaining
10,000 options
Stock options reported following the derivative exercise
Option Term
2031-03-31 expiration
Expiration date of the Non-Qualified Stock Option grant
Vesting Schedule
4 years (1/4 then 1/48 monthly for 36 months)
Vesting terms for the option grant, subject to continued employment
Key Terms
Non-Qualified Stock Option (Right to Buy), derivative security, vesting
3 terms
Non-Qualified Stock Option (Right to Buy) financial
"Security title reported as Non-Qualified Stock Option (Right to Buy)"
derivative security financial
"Transaction code description notes Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
vesting financial
"Stock options will vest over 4 years from the date of the grant"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Cytokinetics (CYTK) EVP Andrew Callos report in this Form 4?
Andrew Callos reported exercising 14,000 stock options at $23.26 per share and selling 14,000 shares at $79.88. The transactions were made under a Rule 10b5-1 trading plan, and he reports 10,000 stock options remaining after the exercise.
What options did Andrew Callos exercise in CYTOKINETICS (CYTK) stock?
He exercised 14,000 Non-Qualified Stock Options with an exercise price of $23.26 per share, converting them into an equal number of Common Stock shares. The options have an expiration date of 2031-03-31, according to the reported derivative security details.
Were Andrew Callos’s CYTOKINETICS (CYTK) trades under a Rule 10b5-1 plan?
Yes. The filing indicates the transactions were effected under a Rule 10b5-1 trading plan. Such plans prearrange trading activity, providing a structured framework for insider sales independent of subsequent material nonpublic information.
What is the vesting schedule of Andrew Callos’s CYTOKINETICS (CYTK) stock options?
The option grant vests over 4 years: 25% of the shares vest on the one-year anniversary of the grant date, and the remaining 75% vest monthly at 1/48 of the total over the next 36 months, subject to continued employment.
How many CYTOKINETICS (CYTK) stock options does Andrew Callos report remaining?
After exercising 14,000 options, Andrew Callos reports 10,000 stock options remaining. This figure reflects the options position following the reported derivative transaction and does not address any separate Common Stock holdings he may have.
AI-generated analysis. How Rhea-AI works. Not financial advice.
